Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€117.60

€117.60

0.000%
-
0.000%
€125.66
 
08:07 / Tradegate WKN: A0YD8Q / Symbol: MRK / Name: Merck & Co / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Merck & Co. Inc. Stock

There is no change in the price for Merck & Co. Inc. today.
The stock is one of the favorites of our community with 49 Buy predictions and 1 Sell predictions.
As a result the target price of 125 € shows a slightly positive potential of 6.29% compared to the current price of 117.6 € for Merck & Co. Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Merck & Co. Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Merck & Co. Inc. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Merck & Co. Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Merck & Co. Inc. 0.000% 1.205% -2.810% 22.884% 19.391% 78.317% 63.333%
Pfizer Inc. 0.450% 3.585% 3.887% -17.515% 2.395% -21.247% -25.873%
Johnson & Johnson 0.200% 1.950% 0.750% -3.874% -3.263% -3.887% 14.493%
Elanco Animal Health Inc. -1.410% -4.949% -27.259% 16.042% -9.364% -57.716% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-16

The financial statements of Merck & Co, a prominent player in the pharmaceutical industry, reflect a company that is performing relatively well in terms of operational efficiency, profitability, and growth. Although Merck faces risks, common to pharmaceutical companies, including R&D expenses, regulatory compliance, and competition, the company appears to be maintaining stable growth over the past years. The following analysis discusses both the positives and negatives associated with the company's financials.

*Pros: *

Revenue Growth: Merck's total revenue has grown consistently over the past three years, indicating a successful expansion and growth strategy. This points to a strong product pipeline and competent market positioning, which are essential factors for success in the pharmaceutical industry.

Comments

Prediction Buy
Perf. (%) 0.34%
Target price 125.000
Change
Ends at 12.07.25

Merck & Co. is a pharmaceutical giant that has been making waves in the industry lately. While they've faced a few setbacks with failed clinical trials, the company's diverse pipeline and impressive portfolio of approved drugs make it a solid investment opportunity. The recent news about their exclusive rights to the prostate cancer candidate opevesostat from partner Orion is particularly exciting, as it showcases Merck's ability to expand its product offerings through strategic partnerships. Additionally, the positive CHMP recommendation for their pulmonary arterial hypertension drug Winrevair in Europe is a testament to the company's strong R&D capabilities. Despite the occasional hiccup, Merck has a proven track record of delivering innovative therapies that have a real impact on people's lives. As an investor, I'm optimistic about the company's long-term prospects and believe it's a buy at the current price point.
Show more

Prediction Buy
Perf. (%) 0.34%
Target price 125.000
Change
Ends at 12.07.25

Merck & Co. is a pharmaceutical giant that has seen its share price hover around $117 recently. While there have been some setbacks, such as the discontinuation of a cancer drug study, the company's diverse portfolio of successful products like Keytruda, Gardasil, and Januvia, as well as promising pipeline candidates, make it an attractive long-term investment. The recent deal to acquire the exclusive rights to Orion's prostate cancer drug opevesostat also demonstrates Merck's strategic focus on expanding its oncology offerings. Additionally, the positive CHMP recommendation for Merck's pulmonary arterial hypertension drug Winrevair in Europe is a positive sign. Overall, Merck's strong fundamentals, diverse product mix, and promising pipeline make it a solid buy for investors with a long-term horizon.
Show more

Prediction Buy
Perf. (%) 0.34%
Target price 130.000
Change
Ends at 12.07.25

Merck & Co. Inc. is a pharmaceutical giant that has been making waves in the industry lately. The recent news around the company's drug development and partnership deals suggests that there could be some exciting times ahead. While the stock has seen some volatility recently due to study failures, the overall picture looks promising. The company's diverse pipeline of products, ranging from cancer treatments to vaccines, provides a solid foundation for growth. Additionally, the exclusive rights to the prostate cancer drug opevesostat from its partner Orion could be a game-changer. With a strong track record and a focus on innovation, Merck seems poised to capitalize on the growing demand for healthcare solutions. As an investor, I'm optimistic about the company's prospects and believe that the current price offers a good entry point. It's like Merck is the quarterback of the pharmaceutical industry, making strategic plays that could lead to touchdowns for investors.
Show more